Taken together, our results show that FGF21 can improve pulmonary vascular remodelling and collagen deposition by inhibiting the negative regulatory effects of miR‐130 on PPARγ and ultimately alleviating pulmonary hypertension. The gene discussed is FGF21; the disease is pulmonary hypertension.